Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $60
Promising Clinical Trial Results Boost Confidence in Arrowhead Pharmaceuticals, Justifying Buy Rating
Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement...
Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) Have Lost 66%, as Stock Drops 9.3% This Past Week
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $45
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)
